Top 5 Takeaways Pneumonic Plague Misdiagnosed Amidst COVID-19: An adult admitted to a Wyoming hospital for respiratory symptoms initially suspected to be COVID-19 was later confirmed to have pneumonic plague.
Tag: Infectious Disease
Top 5 Takeaways Significant Decrease in Mortality Rates Among LTCF Residents: The study found a 69% reduction in COVID-19 mortality rates among long-term care facility (LTCF) residents aged ≥65 years
Top 5 Takeaways Novel OPV2 Shows Genetic Stability: Global genomic surveillance confirms the genetic stability of the novel oral poliovirus vaccine type 2 (nOPV2), maintaining the primary attenuating site’s integrity
Top 5 Takeaways Higher Hospitalization Rates in Disability-Eligible Medicare Beneficiaries: COVID-19-associated hospitalization rates were about 50% higher in disability-eligible beneficiaries compared to those eligible due to age, with rates increasing
Top 5 Takeaways Global Surveillance Enhancements: In 2022–2023, 71.4% of 28 priority countries met national acute flaccid paralysis (AFP) surveillance indicator targets, and environmental surveillance sites increased, supporting the global
Top 5 Takeaways Decline in HIV Testing and Diagnoses: From 2019 to 2020, there was a 17% decrease in new HIV diagnoses reported to the CDC, accompanying a significant decline
Top 5 Takeaways Low Incidence of Severe Illness Post-Paxlovid: Hospitalizations or ED encounters for COVID-19 within 5-15 days after Paxlovid treatment were rare, occurring in <1% of patients, suggesting Paxlovid’s
Top 5 Takeaways Lagevrio and Paxlovid showed effectiveness in preventing hospitalization and death. These oral antiviral drugs have been crucial for patients with mild to moderate COVID-19 who are at
Top 5 Takeaways FDA Approvals and ACIP Recommendations: The FDA issued Emergency Use Authorizations for the Moderna and Pfizer-BioNTech COVID-19 vaccines for children aged 6 months–5 years and 6 months–4
Top 5 Takeaways Increased Protection for Immunocompromised Adults: The updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine offers increased protection against COVID-19-associated hospitalizations for adults aged ≥18 years with immunocompromising conditions. Low